Key result
TAVR is linked to acute thromboinflammatory activation, driven by elevated postprocedural D-dimer and IL-6.
Why the study?
TAVR induces a thromboinflammatory response characterized by hypercoagulability and dynamic platelet alterations, but the integrated mechanisms across systemic, cellular, and transcriptomic levels remain incompletely defined.
Does transcatheter aortic valve replacement (TAVR) induce periprocedural hemostatic, inflammatory, and platelet transcriptomic changes in patients undergoing the procedure?
Observational (n=102)
No
Does transcatheter aortic valve replacement (TAVR) induce periprocedural hemostatic, inflammatory, and platelet transcriptomic changes in patients undergoing the procedure?
Answers are grounded in this paper and cite their sources.
This study provides mechanistic insight into the acute thromboinflammatory milieu following TAVR by demonstrating coordinated systemic coagulation, inflammatory activation, platelet phenotypic alterations, and upregulation of platelet activation transcriptomic pathways.
Backround Transcatheter aortic valve replacement (TAVR) induces a thromboinflammatory response characterized by hypercoagulability and dynamic platelet alterations. The integrated mechanisms underlying these changes remain incompletely defined. Purpose To comprehensively characterize periprocedural hemostatic and inflammatory changes after TAVR across systemic, cellular, and transcriptomic levels. Methods In this prospective single-center study, patients undergoing TAVR were enrolled between September 2022 and July 2024. Blood samples were obtained on the day of the procedure (T0; prior to valve implantation) and at hospital discharge (T1; median 3.5 days, IQR 2–4 days). At both time points, soluble biomarkers were assessed by routine laboratory testing, cellular phenotype by flow cytometry (FACS), and isolated platelets underwent RNA sequencing. Results Soluble biomarkers were assessed in 102 consecutive TAVR patients, with FACS and transcriptomic analysis in a sub-cohort of 32. TAVR induced a pronounced systemic increase in markers of coagulation and inflammation. The most relevant changes were observed for D-dimers (medianΔ 0.67 mg/L [IQRΔ 0.44–1.07]; p = 0.001), von Willebrand factor activity (medianΔ 87% p < 0.0001), fibrinogen (medianΔ 125 mg/dL; p < 0.0001), Il-6 (medianΔ 19.70 ng/l [IQRΔ 10.80–35.25]; p < 0.0001 and Troponin T medianΔ 43.20 ng/l;p < 0.0001, consistent with acute coagulation and inflammatory activation with myocardial injury. At cellular level, platelet count declined (medianΔ −27 × 10³/µL [−54.5 to −5.5]; p < 0.0001), accompanied by reduced GPIIb/IIIa (ΔgeoMFI −275 a.u.; p < 0.0001) and CD62P expression (ΔgeoMFI −98 a.u.; p =0.003), and increased platelet–neutrophil aggregates (CD42a+CD15+, ΔgeoMFI 377.0 a.u. p = 0.036), reflecting platelet phenotypic alteration and enhanced platelet–immune interaction. At the transcriptomic level, RNA sequencing identified 188 upregulated and 508 downregulated differentially expressed transcripts.Gene set enrichment analysis demonstrated upregulation of platelet activation, aggregation, and hemostasis pathways. Over-representation analysis confirmed enrichment of platelet activation–associated genes, including DMTN, FCER1G, MMRN1, SELP, and FUNDC2. Conclusion TAVR induces a coordinated thromboinflammatory response across systemic, cellular, and transcriptomic levels, characterized by systemic coagulation and inflammatory activation, platelet phenotypic alterations, and transcriptional enrichment of platelet activation pathways. Together, these findings provide mechanistic insight into the acute thromboinflammatory milieu associated with the procedure.
No takes yet. Share an insight, caveat, or question.
Hesselbarth et al. (2026) conducted an observational in Aortic valve disease undergoing transcatheter aortic valve replacement (TAVR) (n=102). Transcatheter aortic valve replacement (TAVR) vs. Pre-procedure baseline (prior to valve implantation) was evaluated on Periprocedural hemostatic and inflammatory changes across systemic, cellular, and transcriptomic levels (p=<0.0001). TAVR induced thromboinflammatory activation at discharge, increasing D-dimer and IL-6 while decreasing platelets.
Synapse has enriched 10 related papers. Consider them for comparative context: